{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:59:05Z","timestamp":1774040345791,"version":"3.50.1"},"reference-count":176,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.beha.2023.101464","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:33:31Z","timestamp":1680748411000},"page":"101464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dermatologic complications in transplantation and cellular therapy for acute leukemia"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7449-9524","authenticated-orcid":false,"given":"Shahab","family":"Babakoohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie L.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2023.101464_bib1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","article-title":"Toxic erythema of chemotherapy: a useful clinical term","volume":"59","author":"Bolognia","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib2","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.clindermatol.2015.04.008","article-title":"Baboon syndrome and toxic erythema of chemotherapy: fold (intertriginous) dermatoses","volume":"33","author":"Wolf","year":"2015","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hemonc.2018.09.001","article-title":"Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation","volume":"12","author":"Hunjan","year":"2019","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.beha.2023.101464_bib4","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3791","article-title":"Localized injection-site toxic erythema of chemotherapy: an under-recognized acquaintance revisited","volume":"101","author":"R\u00edos-Vi\u00f1uela","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.beha.2023.101464_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/ced.15165","article-title":"Toxic epidermal necrolysis-like presentation of toxic erythema of chemotherapy","volume":"47","author":"Mehta","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/bmt.2012.218","article-title":"Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant","volume":"48","author":"Parker","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102459","article-title":"Adverse events in 1406 patients receiving 13,780 cycles of azacitidine within the Austrian registry of hypomethylating agents-A prospective cohort study of the AGMT study-group","volume":"14","author":"Leisch","year":"2022","journal-title":"Cancers"},{"issue":"Suppl 4","key":"10.1016\/j.beha.2023.101464_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-011-0021-5","article-title":"Adverse effects of azacitidine: onset, duration, and treatment","volume":"28","author":"Mart\u00ednez-Franc\u00e9s","year":"2011","journal-title":"Adv Ther"},{"key":"10.1016\/j.beha.2023.101464_bib9","article-title":"Reticular skin rash as an adverse effect of 5-azacitidine","volume":"14","author":"Verma","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.beha.2023.101464_bib10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2146\/ajhp110523","article-title":"Azacitidine-associated Sweet's syndrome","volume":"69","author":"Trickett","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.beha.2023.101464_bib11","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/bmj.1.5489.736-d","article-title":"Pigmentation and busulphan therapy","volume":"1","author":"Sprunt","year":"1966","journal-title":"Br Med J"},{"key":"10.1016\/j.beha.2023.101464_bib12","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/bmt.2017.15","article-title":"Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood","volume":"52","author":"Bresters","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib13","first-page":"869","article-title":"Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants","volume":"15","author":"Ljungman","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.beha.2023.101464_bib16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s10549-017-4204-x","article-title":"Chemotherapy-induced irreversible alopecia in early breast cancer patients","volume":"163","author":"Kim","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.beha.2023.101464_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0091-6749(96)70279-8","article-title":"Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients","volume":"97","author":"Popescu","year":"1996","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.beha.2023.101464_bib18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7555\/JBR.26.20110067","article-title":"Cyclosporine A stimulated hair growth from mouse vibrissae follicles in an organ culture model","volume":"26","author":"Xu","year":"2012","journal-title":"J Biomed Res"},{"key":"10.1016\/j.beha.2023.101464_bib19","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1111\/ajt.14337","article-title":"Cutaneous toxicities from transplantation-related medications","volume":"17","author":"Ilyas","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib20","series-title":"VYXEOS\u2122 (daunorubicin and cytarabine) liposome for injection, for intravenous use","year":"2017"},{"key":"10.1016\/j.beha.2023.101464_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1046\/j.1468-3083.2002.00395.x","article-title":"High-dose cytosine arabinoside-induced cutaneous reactions","volume":"16","author":"Cetkovsk\u00e1","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.beha.2023.101464_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jaad.2021.01.096","article-title":"Liposomal cytarabine and daunorubicin (CPX-351\/Vyxeos)-associated distinct purpuric subtype of toxic erythema of chemotherapy: a retrospective review of 54 patients","volume":"86","author":"Stoll","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib23","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/ccr3.3909","article-title":"CPX-351 (Vyxeos(\u00ae)) can cause severe rash in acute myeloid leukemia-A case report","volume":"9","author":"Urbantat","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.beha.2023.101464_bib24","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","article-title":"Maintenance therapy with decitabine after allogeneic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome","volume":"21","author":"Pusic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib25","series-title":"For injection, for intravenous use","year":"2006"},{"key":"10.1016\/j.beha.2023.101464_bib26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00277-003-0624-2","article-title":"FLAG-IDA in the treatment of refractory\/relapsed acute myeloid leukemia: single-center experience","volume":"82","author":"Pastore","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib27","unstructured":"Fludara\u00ae(Fludarabine phosphate)."},{"key":"10.1016\/j.beha.2023.101464_bib28","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1080\/10428190500096989","article-title":"Accelerated growth of skin carcinoma following fludarabine therapy for chronic lymphocytic leukemia","volume":"46","author":"Rashid","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2023.101464_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ajh.10080","article-title":"Aggressive growth of epithelial carcinomas following treatment with nucleoside analogues","volume":"70","author":"Larsen","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1017498","article-title":"Skin cancer outcomes and risk factors in renal transplant recipients: analysis of organ procurement and transplantation network data from 2000 to 2021","volume":"12","author":"Hao","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.12659\/AOT.901556","article-title":"Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation","volume":"22","author":"Aguiar","year":"2017","journal-title":"Ann Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib32","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.tp.0000181195.67084.94","article-title":"Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients","volume":"80","author":"Tricot","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2023.101464_bib33","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1684\/ejd.2021.4108","article-title":"The association between immunosuppression and skin cancer in solid organ transplant recipients: a control-matched cohort study of 2,852 patients","volume":"31","author":"Gibson","year":"2021","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib34","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib35","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CLEP.S146442","article-title":"A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)","volume":"10","author":"Castellsague","year":"2018","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.beha.2023.101464_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jaad.2007.12.037","article-title":"Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation","volume":"58","author":"Rosman","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/sj.bmt.1703695","article-title":"Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy","volume":"30","author":"de Jonge","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib38","series-title":"LEMTRADA\u00ae (alemtuzumab) injection, for intravenous use","year":"2001"},{"key":"10.1016\/j.beha.2023.101464_bib39","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s00415-019-09214-2","article-title":"A case of anaphylaxis to alemtuzumab","volume":"266","author":"Nye","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.beha.2023.101464_bib40","series-title":"THYMOGLOBULIN (anti-thymocyte globulin [rabbit]) for intravenous use","year":"1998"},{"key":"10.1016\/j.beha.2023.101464_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1182\/hematology.2020000098","article-title":"Updates in infection risk and management in acute leukemia","volume":"2020","author":"Logan","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2023.101464_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13223-017-0186-9","article-title":"An avoidable cause of thymoglobulin anaphylaxis","volume":"13","author":"Brabant","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.beha.2023.101464_bib43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2023.101464_bib44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2023.101464_bib45","series-title":"BLINCYTO\u00ae (blinatumomab) for injection, for intravenous use","year":"2014"},{"key":"10.1016\/j.beha.2023.101464_bib46","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jdcr.2017.01.017","article-title":"Blinatumomab-associated vasculitis","volume":"3","author":"Liau","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.beha.2023.101464_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev"},{"key":"10.1016\/j.beha.2023.101464_bib48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101464_bib49","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101464_bib50","first-page":"137","article-title":"FLT3 inhibitors as maintenance therapy after allogeneic stem-cell transplantation","volume":"12","author":"Blackmon","year":"2022","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.beha.2023.101464_bib51","series-title":"XOSPATA\u00ae (gilteritinib) tablets, for oral use","year":"2018"},{"key":"10.1016\/j.beha.2023.101464_bib52","series-title":"RYDAPT\u00ae (midostaurin) capsules, for oral use","year":"2017"},{"key":"10.1016\/j.beha.2023.101464_bib53","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/20009666.2020.1766818","article-title":"Sweet's syndrome in a granulocytopenic patient with acute myeloid leukemia on FLT3 inhibitor","volume":"10","author":"Paudel","year":"2020","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"10.1016\/j.beha.2023.101464_bib54","article-title":"A rare case of midostaurin-associated sweet's syndrome","volume":"2022","author":"Yasin","year":"2022","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib55","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib56","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib57","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101464_bib58","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101464_bib59","series-title":"For oral use","year":"2018"},{"key":"10.1016\/j.beha.2023.101464_bib60","series-title":"IDHIFA\u00ae (enasidenib) tablets, for oral use","year":"2017"},{"key":"10.1016\/j.beha.2023.101464_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106970","article-title":"Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia","volume":"123","author":"Parisi","year":"2022","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2023.101464_bib62","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2020-138832","article-title":"Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse","volume":"136","author":"Kent","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib64","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib65","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1182\/blood-2019-130854","article-title":"Does venetoclax cause vitiligo?","volume":"134","author":"Baddam","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib66","first-page":"11","article-title":"Geographic tongue induced by venetoclax in a patient with chronic lymphocytic leukemia","volume":"12","author":"Krispinsky","year":"2019","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib67","series-title":"VENCLEXTA\u00ae (venetoclax tablets) for oral use","year":"2016"},{"key":"10.1016\/j.beha.2023.101464_bib68","article-title":"Adverse effects of total body irradiation: a two-decade, single institution analysis","volume":"6","author":"Pearlman","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib69","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/sj.bmt.1705817","article-title":"Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation","volume":"40","author":"Machado","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib71","doi-asserted-by":"crossref","DOI":"10.1007\/s44228-023-00029-7","article-title":"Prophylactic trimethoprim-sulfamethoxazole for allogeneic hematopoietic stem cell transplant recipients during the pre-engraftment period","author":"Gaffney","year":"2023","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.beha.2023.101464_bib72","article-title":"An adverse drug reaction to trimethoprim-sulfamethoxazole revealing primary HIV: a case report and literature review","volume":"2015","author":"Meyer","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"10.1016\/j.beha.2023.101464_bib73","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archinte.163.4.402","article-title":"Trimethoprim-sulfamethoxazole revisited","volume":"163","author":"Masters","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.beha.2023.101464_bib74","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101464_bib75","doi-asserted-by":"crossref","DOI":"10.1007\/s10238-022-00868-3","article-title":"Feasibility of trimethoprim\/sulfamethoxazole desensitization therapy in hematological diseases","author":"Negishi","year":"2022","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.beha.2023.101464_bib76","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.beha.2023.101464_bib77","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.medmal.2011.09.016","article-title":"Phototoxicity and photocarcinogenesis associated with voriconazole","volume":"41","author":"Epaulard","year":"2011","journal-title":"Med Maladies Infect"},{"key":"10.1016\/j.beha.2023.101464_bib78","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jaad.2014.10.023","article-title":"Voriconazole phototoxicity in children: a retrospective review","volume":"72","author":"Sheu","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib79","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1345\/aph.1L343","article-title":"Appearance of anaphylactic shock after long-term intravenous itraconazole treatment","volume":"43","author":"Chen","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.beha.2023.101464_bib80","doi-asserted-by":"crossref","DOI":"10.5070\/D3209023901","article-title":"Toxic epidermal necrolysis due to voriconazole: case report and review","volume":"20","author":"Gomulka","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.beha.2023.101464_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2009.09.033","article-title":"Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole","volume":"62","author":"Cowen","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib82","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/bjd.13862","article-title":"Voriconazole N-oxide and its ultraviolet B photoproduct sensitize keratinocytes to ultraviolet A","volume":"173","author":"Ona","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.08.010","article-title":"Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: a systematic review and meta-analysis","volume":"80","author":"Tang","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib84","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.healun.2012.02.033","article-title":"High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients","volume":"31","author":"Singer","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib85","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ijd.14820","article-title":"Presence of human papillomavirus DNA in voriconazole-associated cutaneous squamous cell carcinoma","volume":"59","author":"Nguyen","year":"2020","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib86","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/cid\/cit940","article-title":"Voriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipients","volume":"58","author":"Williams","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.beha.2023.101464_bib87","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1016\/j.jid.2018.09.002","article-title":"Research techniques made simple: CAR T-cell therapy","volume":"138","author":"Siddiqi","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib88","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2023.101464_bib89","unstructured":"Zhang B. Kymriah: FDA approves first gene therapy in the United States."},{"key":"10.1016\/j.beha.2023.101464_bib90","series-title":"YESCARTA package insert","year":"2018"},{"key":"10.1016\/j.beha.2023.101464_bib91","unstructured":"Food U, Administration D. Package insert: breyanzi. WWW-document: https:\/\/www fda gov\/media\/145711\/download Date of access. 2021:May-21."},{"key":"10.1016\/j.beha.2023.101464_bib92","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2016.06.062","article-title":"Evaluating the skin in patients undergoing chimeric antigen receptor modified T-cell therapy","volume":"75","author":"Rubin","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib93","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamadermatol.2020.0636","article-title":"Bullous and exanthematous lesions associated with chimeric antigen receptor T-cell therapy in a patient with diffuse large B-cell lymphoma","volume":"156","author":"Hu","year":"2020","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.beha.2023.101464_bib94","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaad.2021.07.017","article-title":"Cutaneous manifestations of chimeric antigen receptor T-cell therapy: an introduction for dermatologists","volume":"87","author":"Nusbaum","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib95","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/j.bbmt.2016.12.455","article-title":"Acute GvHD incidence and outcome: single center experience","volume":"23","author":"Elsabbagh","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib96","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/bmt.2013.59","article-title":"Prognosis of grade 3\u20134 acute GVHD continues to be dismal","volume":"48","author":"Jamani","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib97","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fimmu.2017.00079","article-title":"Pathophysiology of GvHD and other HSCT-related major complications","volume":"8","author":"Ghimire","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.beha.2023.101464_bib98","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute graft-versus-host disease: a bench-to-bedside update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101464_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40257-017-0306-9","article-title":"Cutaneous graft-versus-host disease: diagnosis and treatment","volume":"19","author":"Strong Rodrigues","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib101","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2023.101464_bib102","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/archderm.136.6.717","article-title":"Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation","volume":"136","author":"Zhou","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib103","first-page":"367","article-title":"Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors","author":"Lerner","year":"1974","journal-title":"Transplant Proc"},{"key":"10.1016\/j.beha.2023.101464_bib104","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/00000478-199709000-00002","article-title":"Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease","volume":"21","author":"Kohler","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.beha.2023.101464_bib105","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0190-9622(98)70115-X","article-title":"Rush\u201d skin biopsy specimens in a tertiary medical center: diagnostic yield and clinical utility","volume":"38","author":"Barksdale","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib106","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1365-2141.2012.09129.x","article-title":"D iagnosis and management of acute graft\u2010versus\u2010host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101464_bib107","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s13671-019-00280-3","article-title":"Inpatient management of mucocutaneous GVHD","volume":"8","author":"Vaidya","year":"2019","journal-title":"Curr Dermatol Rep"},{"key":"10.1016\/j.beha.2023.101464_bib108","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.bbmt.2018.12.130","article-title":"Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 REACH1 trial","volume":"25","author":"Jagasia","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib109","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjh.14537","article-title":"The role of extracorporeal photopheresis in the management of cutaneous T\u2010cell lymphoma, graft\u2010versus\u2010host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society","volume":"177","author":"Alfred","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101464_bib110","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1590\/S0100-879X2006005000145","article-title":"Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease","volume":"40","author":"Nogueira","year":"2007","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.beha.2023.101464_bib111","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00277-016-2854-0","article-title":"Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation","volume":"96","author":"Hattori","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib112","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/bbmt.2002.v8.pm11858189","article-title":"Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease","volume":"8","author":"MacMillan","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib113","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/00007890-200112270-00010","article-title":"Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease1","volume":"72","author":"Benito","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.beha.2023.101464_bib114","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1200\/JCO.2005.06.130","article-title":"Pentostatin in steroid-refractory acute graft-versus-host disease","volume":"23","author":"Bolanos-Meade","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3324\/haematol.2015.129650","article-title":"Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation","volume":"100","author":"Kekre","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2023.101464_bib116","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.beha.2008.02.007","article-title":"Graft-versus-host disease after donor leukocyte infusions: presentation and management","volume":"21","author":"Frey","year":"2008","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2023.101464_bib117","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib118","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib119","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib120","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib121","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/archderm.138.7.924","article-title":"Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients","volume":"138","author":"Pe\u00f1as","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib122","first-page":"5098","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood, J Am Soc Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib123","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjd.12828","article-title":"Skin ulcers related to chronic graft\u2010versus\u2010host disease: clinical findings and associated morbidity","volume":"171","author":"Jachiet","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib124","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.bbmt.2015.03.024","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report","volume":"21","author":"Carpenter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib125","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/jdv.12737","article-title":"Consensus on performing skin biopsies, laboratory workup, evaluation of tissue samples and reporting of the results in patients with suspected cutaneous graft\u2010versus\u2010host disease","volume":"29","author":"Hillen","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.beha.2023.101464_bib126","first-page":"606","article-title":"How we treat chronic graft-versus-host disease. Blood","volume":"125","author":"Flowers","year":"2015","journal-title":"J Am Soc Hematol."},{"key":"10.1016\/j.beha.2023.101464_bib127","first-page":"2243","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood","volume":"130","author":"Miklos","year":"2017","journal-title":"J Am Soc Hematol."},{"key":"10.1016\/j.beha.2023.101464_bib128","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000488238","article-title":"Extracorporeal photopheresis: an efficacious and well-tolerated treatment for cutaneous and oral mucosal chronic graft-versus-host disease","volume":"234","author":"Richet","year":"2018","journal-title":"Dermatology"},{"key":"10.1016\/j.beha.2023.101464_bib129","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101464_bib130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/ctr.12405","article-title":"Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft\u2010vs.\u2010host disease in adult patients in","volume":"28","author":"Iida","year":"2014","journal-title":"J apan. Clinical transplantation."},{"key":"10.1016\/j.beha.2023.101464_bib131","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bbmt.2008.12.493","article-title":"First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate","volume":"15","author":"Wang","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib132","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1200\/JCO.2007.10.8456","article-title":"Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease","volume":"25","author":"Jacobsohn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib133","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2005.05616.x","article-title":"Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft\u2010versus\u2010host disease","volume":"130","author":"Couriel","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101464_bib134","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease","volume":"21","author":"Baird","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib135","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4065\/mcp.2010.0099","article-title":"Paraneoplastic syndromes: an approach to diagnosis and treatment","volume":"85","author":"Pelosof","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.beha.2023.101464_bib136","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3892\/ijo.2013.1874","article-title":"Insight into Sweet's syndrome and associated-malignancy: a review of the current literature","volume":"42","author":"Raza","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.beha.2023.101464_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.09.013","article-title":"Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center","volume":"78","author":"Nelson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib138","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-2-34","article-title":"Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis","volume":"2","author":"Cohen","year":"2007","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.beha.2023.101464_bib139","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaad.2013.06.023","article-title":"Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients","volume":"69","author":"Rochet","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib140","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1365-4632.2004.02287.x","article-title":"Bullous variant of Sweet's syndrome","volume":"44","author":"Voelter-Mahlknecht","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib141","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2005.03.001","article-title":"Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis","volume":"52","author":"Cohen","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib142","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0190-9622(94)70215-2","article-title":"Sweet's syndrome (acute febrile neutrophilic dermatosis)","volume":"31","author":"von den Driesch","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib143","first-page":"167","article-title":"Diagnostic criteria for Sweet's syndrome","volume":"37","author":"Su","year":"1986","journal-title":"Cutis"},{"key":"10.1016\/j.beha.2023.101464_bib144","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00128071-200203020-00005","article-title":"Sweet's syndrome: a review of current treatment options","volume":"3","author":"Cohen","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/ijd.13232","article-title":"Sweet's syndrome: a retrospective study of 90 cases from a tertiary care center","volume":"55","author":"Amouri","year":"2016","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib146","first-page":"125","article-title":"The use of pulse methylprednisolone and chlorambucil in the treatment of Sweet's syndrome","volume":"44","author":"Case","year":"1989","journal-title":"Cutis"},{"key":"10.1016\/j.beha.2023.101464_bib147","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/1346-8138.15312","article-title":"Efficacy of acitretin in the treatment of reactive neutrophilic dermatoses in adult-onset immunodeficiency due to interferon-gamma autoantibody","volume":"47","author":"Rujiwetpongstorn","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib148","first-page":"54","article-title":"Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate","volume":"81","author":"Altomare","year":"1996","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2023.101464_bib149","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2230.1994.tb01187.x","article-title":"Sweet's syndrome--therapy with cyclosporin","volume":"19","author":"von den Driesch","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib150","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/12034754221111992","article-title":"Evaluation of methotrexate in the management of Sweet syndrome","volume":"26","author":"Hrin","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.beha.2023.101464_bib151","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1016\/j.jaad.2004.12.041","article-title":"Thalidomide in the treatment of recalcitrant Sweet's syndrome associated with myelodysplasia","volume":"53","author":"Browning","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib152","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000326112","article-title":"Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret\u00ae) in a case of refractory Sweet's syndrome","volume":"222","author":"Kluger","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.beha.2023.101464_bib153","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New practical aspects of Sweet syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib154","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1365-2133.2011.10565.x","article-title":"Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients","volume":"165","author":"Binus","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib155","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/j.1468-3083.2009.03199.x","article-title":"Pyoderma gangrenosum: an updated review","volume":"23","author":"Ruocco","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.beha.2023.101464_bib156","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005792-200001000-00004","article-title":"Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions","volume":"79","author":"Bennett","year":"2000","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.beha.2023.101464_bib157","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2310\/7750.2011.10119","article-title":"Pyoderma gangrenosum: the great pretender and a challenging diagnosis","volume":"15","author":"Wong","year":"2011","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.beha.2023.101464_bib158","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-4632.2004.02128.x","article-title":"Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria","volume":"43","author":"Su","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib159","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa013383","article-title":"Skin ulcers misdiagnosed as pyoderma gangrenosum","volume":"347","author":"Weenig","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.beha.2023.101464_bib160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/11595240-000000000-00000","article-title":"Etiology and management of pyoderma gangrenosum: a comprehensive review","volume":"13","author":"Ahronowitz","year":"2012","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib161","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jaad.2016.06.016","article-title":"Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: a prospective cohort study","volume":"75","author":"Thomas","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib162","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.beha.2023.101464_bib163","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","article-title":"Clinical features and treatment of peristomal pyoderma gangrenosum","volume":"284","author":"Hughes","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.beha.2023.101464_bib164","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-662-44000-1_1","article-title":"Infections in patients with acute leukemia","author":"Rolston","year":"2015","journal-title":"Infect Hematol"},{"key":"10.1016\/j.beha.2023.101464_bib165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-59745-438-4_19","article-title":"Infection in the hematopoietic stem cell transplant recipient","author":"Marty","year":"2008","journal-title":"Hematopoietic Stem Cell Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib166","article-title":"Fungal infections in hematopoietic stem-cell transplant patients: a review of epidemiology, diagnosis, and management","volume":"8","author":"Rahi","year":"2021","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.beha.2023.101464_bib167","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/bmt.2008.386","article-title":"Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia","volume":"43","author":"Styczynski","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101464_bib168","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1177\/147323000403200410","article-title":"Density of Demodex folliculorum in haematological malignancies","volume":"32","author":"Seyhan","year":"2004","journal-title":"J Int Med Res"},{"key":"10.1016\/j.beha.2023.101464_bib169","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jdcr.2018.09.013","article-title":"Sparing of the scalp in severe Demodex folliculitis after stem cell transplantation","volume":"4","author":"Chen","year":"2018","journal-title":"JAAD Case Reports"},{"key":"10.1016\/j.beha.2023.101464_bib170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025867","article-title":"Acute myeloid leukaemia presenting with ecthyma gangrenosum as the first manifestation: a case report","volume":"100","author":"Hadano","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.beha.2023.101464_bib171","first-page":"27","article-title":"Leukemia cutis\u2013epidemiology, clinical presentation, and differential diagnoses","volume":"10","author":"Wagner","year":"2012","journal-title":"JDDG J der Deutschen Dermatol Gesellschaft"},{"key":"10.1016\/j.beha.2023.101464_bib172","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jamadermatol.2019.0052","article-title":"Association of leukemia cutis with survival in acute myeloid leukemia","volume":"155","author":"Wang","year":"2019","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.beha.2023.101464_bib173","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jid.2018.10.025","article-title":"Who needs a skin exam? Skin cancers in allogeneic hematopoietic stem cell transplant recipients in the contemporary era","volume":"139","author":"de Masson","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib174","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jamadermatol.2020.0559","article-title":"Risk factors for keratinocyte carcinoma in recipients of allogeneic hematopoietic cell transplants","volume":"156","author":"Scott","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.beha.2023.101464_bib175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jamadermatol.2015.3902","article-title":"Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study","volume":"152","author":"Omland","year":"2016","journal-title":"JAMA dermatology"},{"key":"10.1016\/j.beha.2023.101464_bib176","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.17219\/acem\/126739","article-title":"Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures","volume":"29","author":"Szlauer-Stefa\u0144ska","year":"2020","journal-title":"Adv Clin Exp Med"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000257?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000257?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:40Z","timestamp":1761498520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":176,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1521692623000257"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101464","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatologic complications in transplantation and cellular therapy for acute leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101464"}}